| |||||||||||||||
- Description
- Phenotype
- Genes & alleles
- Genotyping
- Health & husbandry
- References
- Purchasing information
- Terms of Use
Description
The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.
Strain Information
Former Names B10.Cg Hc1 H2d H2-T18c-Tg(Ins2-HA)165Bri/ShrmJ (Changed: 18-JAN-06 ) Type Congenic; Major Histocompatibility Congenic; Mutant Strain; Transgenic; Additional information on Genetically Engineered and Mutant Mice. Visit our online Nomenclature tutorial. Additional information on Congenic nomenclature. Species laboratory mouse Background Strain B10.D2-Hc1 H2d H2-T18c/nSn Donor Strain (C57BL/6 x SJL)F2 H2 Haplotype d Generation N10F20+F2+N1p Donating Investigator Linda Sherman, The Scripps Research Institute Appearance
black
Related Genotype: A/? Tyrc/TyrcDescription
Transgenic mice are viable, fertile, normal in size, normoglycemic and do not display any gross physical or behavioral abnormalities. Mice homozygote for the transgene have silver grey fur color. Hemizygous and wildtype mice are black. Immunohistochemistry reveals pancreatic islet cell expression of the transgene and no expression in the spleen, kidney or thymus. Isolated islets stain normally for insulin and are morphologically indistinguishable from control islets. Additional functional studies found no expression in bone marrow. Histology revealed no insulitis and the single transgenic mice do not become diabetic. T-cell proliferation assays, Cytotoxic Lymphocyte (CTL) assays, and adoptive transfer studies performed using transgenic mice indicate significantly reduced class 1 and class II T-cell responses compared to controls. Hemagglutination inhibition assays of sera from HA primed transgenic mice indicate antibody titers slightly lower but nearly equivalent to HA primed control mice. Antibody titers of all transgenic mice tested were significantly higher than preimmune levels. When mated with Tg(TcraCl4,TcrbCl4) mice, the double transgenic neonates become spontaneously diabetic after birth and die within 10 days.This is a good model for studying peripheral tolerance.
Development
B10.Cg-H2d Tg(Ins2-HA)165Bri/ShrmJ expresses influenza hemagglutinin (HA) molecule from the well characterized influenza A/PR/8/34 under the control of the rat insulin 2 promoter (Ins2). This transgene was injected into (C57BL/6J x SJL)F2 oocytes. Resulting progeny from founder line 2917-5 was backcrossed to H-2d stains BALB/cBy for 10 generations and B10.D2-Hc1 H2d H2-T18c/nSnJ) for 10 generations prior to intercrossing. In 2005, t he Jackson Laboratory received B10.Cg-H2d Tg(Ins2-HA)165Bri/ShrmJ at generation N10F20.
Control Information
| Control | ||
|---|---|---|
| 000463 B10.D2-Hc1 H2d H2-T18c/nSnJ | (approximate) | |
| Stock number 000463 - B10.D2-Hc1 H2d H2-T18c/nSnJ serves as an approximate control. | ||
| Considerations for Choosing Controls | ||
Related Strains
Strains carrying H2d allele
005308 B10.Cg-H2d Tg(TcraCl4,TcrbCl4)1Shrm/ShrmJ 005895 B10.Cg-Thy1a H2d Tg(TcraCl1,TcrbCl1)1Shrm/J 000462 B10.D2-H2d/n2SnJ 000460 B10.D2-Hc0 H2d H2-T18c/o2SnJ 000461 B10.D2-Hc0 H2d H2-T18c/oSnJ 000463 B10.D2-Hc1 H2d H2-T18c/nSnJ 003147 B10.D2-Hc1 H2d H2-T18c/nSnJ-Tg(DO11.10)10Dlo/J 000360 B6.C-H2d Mdmg1BALB/cBy/aByJ 000359 B6.C-H2d/bByJ 001893 BRVR.D2-H2d/J 000437 D1.C-H2d H2-T18c/SnJ 003153 WLC.C-H2d.GR-Mtv2/MorJ 003154 WLC.C-H2d/MorJ View Strains carrying H2d (13 strains)
005533 C.Cg-Tg(Ins2-HA)165Bri/ShrmJ 005685 NOD.Cg-Tg(Ins2-HA)165Bri/ShrmJ
Phenotype
Phenotype Information
assigned by genotype
Tg(Ins2-HA)165Bri/0
B10.Cg- H2d Tg(Ins2-HA)165Bri/ShrmJ
- immune system phenotype
- *normal* immune system phenotype (MGI Ref ID J:86430)
- mice exhibit no evidence of autoimmunity
- abnormal CD4-positive T cell physiology (MGI Ref ID J:86430)
- mice exhibit decreased HA-specific response compared with wild-type mice
- however, mice that are irradiated and transplanted with wild-type lymphocyte mount a CD4+ T cells response to HA
- decreased T cell proliferation (MGI Ref ID J:86430)
- following priming with HA peptides
- endocrine/exocrine gland phenotype
- *normal* endocrine/exocrine gland phenotype (MGI Ref ID J:86430)
- islet beta cells exhibit normal morphology
- hematopoietic system phenotype
- decreased T cell proliferation (MGI Ref ID J:86430)
- following priming with HA peptides
This mouse can be used to support research in many areas including:
H2d relatedImmunology and Inflammation Research
CD Antigens, Antigen Receptors, and Histocompatibility Markers
Inflammation
Rearranged Antigen-Specific T Cell Receptor Transgenes
T Cell Receptor Signaling Defects
Research Tools
Cancer Research
specific T cell deficiency
tumor immunology
Diabetes and Obesity Research
Immunology and Inflammation Research
T Cell Receptor Transgenics
Immunology and Inflammation Research
CD Antigens, Antigen Receptors, and Histocompatibility Markers
Genes & Alleles
Gene & Allele Information
| Allele Symbol | H2d | ||
|---|---|---|---|
| Allele Name | d variant | ||
| Allele Type | Spontaneous | ||
| Gene Symbol and Name | H2, histocompatibility-2, MHC | ||
| Chromosome | 17 | ||
| Gene Common Name(s) | H-2; MHC-II; | ||
| General Note | The d variant has been observed in the following strains: DBA/2, DBA/2J BALB/c, BALB/cByJ, BALB/cJ, C57BLKS, NZB. | ||
| Allele Symbol | Tg(Ins2-HA)165Bri | ||
| Allele Name | transgene insertion 165, Ralph Brinster | ||
| Allele Type | Transgenic (random, expressed) | ||
| Common Name(s) | 2917-5; Ins-HA; InsHA; Tg(Ins-2,HA)Bri165; | ||
| Mutation Made By | Ralph Brinster, University of Pennsylvania | ||
| Expressed Gene | HA, influenza hemagglutinin, | ||
| Promoter | Ins2, insulin 2, rat | ||
| Molecular Note | The transgenic construct consisted of the rat insulin 2 promoter fused to sequence encoding influenza hemagglutinin (HA) followed by the 3' untranslated region and polyadenylation signal from the H2-Ea. HA was from influenza A/PR/8/34. This rat insulin 2 promoter is active in pancreatic beta-cells. [MGI Ref ID J:86430] | ||
Genotyping
Genotyping Information
Genotyping Protocols
Tg(Ins2-HA)165Bri, Standard PCR
Helpful Links
Genotyping resources and troubleshooting
References
References
Selected Reference(s)
Lo D; Freedman J; Hesse S; Palmiter RD; Brinster RL; Sherman LA. 1992. Peripheral tolerance to an islet cell-specific hemagglutinin transgene affects both CD4+ and CD8+ T cells. Eur J Immunol 22(4):1013-22. [PubMed: 1348026] [MGI Ref ID J:86430]
Additional References
H2d relatedTg(Ins2-HA)165Bri relatedAddis-Lieser E; Kohl J; Chiaramonte MG. 2005. Opposing regulatory roles of complement factor 5 in the development of bleomycin-induced pulmonary fibrosis. J Immunol 175(3):1894-902. [PubMed: 16034133] [MGI Ref ID J:107269]
Bakir HY; Tomiyama-Miyaji C; Watanabe H; Nagura T; Kawamura T; Sekikawa H; Abo T. 2006. Reasons why DBA/2 mice are resistant to malarial infection: expansion of CD3int B220+ gammadelta T cells with double-negative CD4- CD8- phenotype in the liver. Immunology 117(1):127-35. [PubMed: 16423048] [MGI Ref ID J:106141]
Bhadra S; Lozano MM; Payne SM; Dudley JP. 2006. Endogenous MMTV Proviruses Induce Susceptibility to Both Viral and Bacterial Pathogens. PLoS Pathog 2(12):e128. [PubMed: 17140288] [MGI Ref ID J:120299]
Buhlmann JE; Gonzalez M; Ginther B; Panoskaltsis-Mortari A; Blazar BR; Greiner DL; Rossini AA; Flavell R; Noelle RJ. 1999. Cutting edge: sustained expansion of CD8+ T cells requires CD154 expression by Th cells in acute graft versus host disease. J Immunol 162(8):4373-6. [PubMed: 10201970] [MGI Ref ID J:119788]
Chiorazzi N; Fox DA; Katz DH. 1977. Hapten-specific IgE antibody responses in mice. VII. Conversion of IgE non-responder strains to IgE responders by elimination of suppressor T cell activity. J Immunol 118(1):48-54. [PubMed: 299762] [MGI Ref ID J:5739]
Clarke SR; Barnden M; Kurts C; Carbone FR; Miller JF; Heath WR. 2000. Characterization of the ovalbumin-specific TCR transgenic line OT-I: MHC elements for positive and negative selection. Immunol Cell Biol 78(2):110-7. [PubMed: 10762410] [MGI Ref ID J:133645]
Croxford AL; Akilli-Ozturk O; Rieux-Laucat F; Forster I; Waisman A; Buch T. 2008. MHC-restricted T cell receptor signaling is required for alphabeta TCR replacement of the pre T cell receptor. Eur J Immunol 38(2):391-9. [PubMed: 18203137] [MGI Ref ID J:131357]
Dalloul AH; Ngo K; Fung-Leung WP. 1996. CD4-negative cytotoxic T cells with a T cell receptor alpha/beta intermediate expression in CD8-deficient mice. Eur J Immunol 26(1):213-8. [PubMed: 8566069] [MGI Ref ID J:112982]
El-Sawy T; Belperio JA; Strieter RM; Remick DG; Fairchild RL. 2005. Inhibition of polymorphonuclear leukocyte-mediated graft damage synergizes with short-term costimulatory blockade to prevent cardiac allograft rejection. Circulation 112(3):320-31. [PubMed: 15998678] [MGI Ref ID J:117219]
Fischer Lindahl K. 1997. On naming H2 haplotypes: functional significance of MHC class Ib alleles. Immunogenetics 46(1):53-62. [PubMed: 9148789] [MGI Ref ID J:41130]
Ford MS; Zhang ZX; Chen W; Zhang L. 2006. Double-negative T regulatory cells can develop outside the thymus and do not mature from CD8+ T cell precursors. J Immunol 177(5):2803-9. [PubMed: 16920915] [MGI Ref ID J:139556]
Fu G; Vallee S; Rybakin V; McGuire MV; Ampudia J; Brockmeyer C; Salek M; Fallen PR; Hoerter JA; Munshi A; Huang YH; Hu J; Fox HS; Sauer K; Acuto O; Gascoigne NR. 2009. Themis controls thymocyte selection through regulation of T cell antigen receptor-mediated signaling. Nat Immunol 10(8):848-56. [PubMed: 19597499] [MGI Ref ID J:151074]
Gershwin ME; Castles JJ; Ikeda RM; Erickson K; Montero J. 1979. Studies of congenitally immunologic mutant New Zealand mice. I. Autoimmune features of hereditarily asplenic (Dh/+) NZB mice; reduction of naturally occurring thymocytotoxic antibody and normal suppressor function. J Immunol 122(2):710-7. [PubMed: 310848] [MGI Ref ID J:12036]
Ghendler Y; Hussey RE; Witte T; Mizoguchi E; Clayton LK; Bhan AK; Koyasu S; Chang HC; Reinherz EL. 1997. Double-positive T cell receptor(high) thymocytes are resistant to peptide/major histocompatibility complex ligand-induced negative selection. Eur J Immunol 27(9):2279-89. [PubMed: 9341770] [MGI Ref ID J:133112]
Gubbels MR; Jorgensen TN; Metzger TE; Menze K; Steele H; Flannery SA; Rozzo SJ; Kotzin BL. 2005. Effects of MHC and gender on lupus-like autoimmunity in Nba2 congenic mice. J Immunol 175(9):6190-6. [PubMed: 16237116] [MGI Ref ID J:119371]
Klein J; Figueroa F; David CS. 1983. H-2 haplotypes, genes and antigens: second listing. II. The H-2 complex. Immunogenetics 17(6):553-96. [PubMed: 6407984] [MGI Ref ID J:7097]
Krupnick AS; Gelman AE; Barchet W; Richardson S; Kreisel FH; Turka LA; Colonna M; Patterson GA; Kreisel D. 2005. Murine vascular endothelium activates and induces the generation of allogeneic CD4+25+Foxp3+ regulatory T cells. J Immunol 175(10):6265-70. [PubMed: 16272276] [MGI Ref ID J:119348]
Laky K; Lewis JM; Tigelaar RE; Puddington L. 2003. Distinct requirements for IL-7 in development of TCR gamma delta cells during fetal and adult life. J Immunol 170(8):4087-94. [PubMed: 12682238] [MGI Ref ID J:125438]
Legge KL; Braciale TJ. 2005. Lymph node dendritic cells control CD8+ T cell responses through regulated FasL expression. Immunity 23(6):649-59. [PubMed: 16356862] [MGI Ref ID J:113311]
Mendiratta SK; Kovalik JP; Hong S; Singh N; Martin WD; Van Kaer L. 1999. Peptide dependency of alloreactive CD4+ T cell responses. Int Immunol 11(3):351-60. [PubMed: 10221647] [MGI Ref ID J:110542]
Miyashita N; Migita S; Moriwaki K. 1987. Effects of H-2 complex and non-H-2 background on urethane-induced chromosomal aberrations in mice. Mutat Res 176(1):59-67. [PubMed: 3099189] [MGI Ref ID J:109945]
Murphy DB. 1986. Overview: the murine MHC. In: Handbook of Experimental Immunology. Vol. 3, Genetic and Molecular Immunology. Blackwell Scientific Publ., Oxford. [MGI Ref ID J:30731]
Murphy WJ; Raziuddin A; Mason L; Kumar V; Bennett M; Longo DL. 1995. NK cell subsets in the regulation of murine hematopoiesis. I. 5E6+ NK cells promote hematopoietic growth in H-2d strain mice. J Immunol 155(6):2911-7. [PubMed: 7673708] [MGI Ref ID J:28582]
Oberg L; Johansson S; Michaelsson J; Tomasello E; Vivier E; Karre K; Hoglund P. 2004. Loss or mismatch of MHC class I is sufficient to trigger NK cell-mediated rejection of resting lymphocytes in vivo - role of KARAP/DAP12-dependent and -independent pathways. Eur J Immunol 34(6):1646-53. [PubMed: 15162434] [MGI Ref ID J:115484]
Porcellini S; Traggiai E; Schenk U; Ferrera D; Matteoli M; Lanzavecchia A; Michalak M; Grassi F. 2006. Regulation of peripheral T cell activation by calreticulin. J Exp Med 203(2):461-71. [PubMed: 16492806] [MGI Ref ID J:119147]
Poulin LF; Habran C; Stordeur P; Goldman M; McKenzie A; Van Snick J; Renauld JC; Braun MY. 2005. Interleukin-9 stimulates the production of interleukin-5 in CD4+ T cells. Eur Cytokine Netw 16(3):233-9. [PubMed: 16266865] [MGI Ref ID J:115764]
Reed-Loisel LM; Sullivan BA; Laur O; Jensen PE. 2005. An MHC class Ib-restricted TCR that cross-reacts with an MHC class Ia molecule. J Immunol 174(12):7746-52. [PubMed: 15944277] [MGI Ref ID J:109978]
Rodrigues OR; Moura RA; Gomes-Pereira S; Santos-Gomes GM. 2006. H-2 complex influences cytokine gene expression in Leishmania infantum-infected macrophages. Cell Immunol 243(2):118-26. [PubMed: 17316586] [MGI Ref ID J:120728]
Santiago ML; Montano M; Benitez R; Messer RJ; Yonemoto W; Chesebro B; Hasenkrug KJ; Greene WC. 2008. Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection. Science 321(5894):1343-6. [PubMed: 18772436] [MGI Ref ID J:138778]
Sho M; Yamada A; Najafian N; Salama AD; Harada H; Sandner SE; Sanchez-Fueyo A; Zheng XX; Strom TB; Sayegh MH. 2002. Physiological mechanisms of regulating alloimmunity: cytokines, CTLA-4, CD25+ cells, and the alloreactive T cell clone size. J Immunol 169(7):3744-51. [PubMed: 12244168] [MGI Ref ID J:120408]
Sutton VR; Waterhouse NJ; Browne KA; Sedelies K; Ciccone A; Anthony D; Koskinen A; Mullbacher A; Trapani JA. 2007. Residual active granzyme B in cathepsin C-null lymphocytes is sufficient for perforin-dependent target cell apoptosis. J Cell Biol 176(4):425-33. [PubMed: 17283185] [MGI Ref ID J:119725]
Ueno T; Habicht A; Clarkson MR; Albin MJ; Yamaura K; Boenisch O; Popoola J; Wang Y; Yagita H; Akiba H; Ansari MJ; Yang J; Turka LA; Rothstein DM; Padera RF; Najafian N; Sayegh MH. 2008. The emerging role of T cell Ig mucin 1 in alloimmune responses in an experimental mouse transplant model. J Clin Invest 118(2):742-51. [PubMed: 18172549] [MGI Ref ID J:131045]
Varadhachary AS; Monestier M; Salgame P. 2001. Reciprocal induction of IL-10 and IL-12 from macrophages by low-density lipoprotein and its oxidized forms. Cell Immunol 213(1):45-51. [PubMed: 11747355] [MGI Ref ID J:115363]
Venkatesan P; Finch RG; Wakelin D. 1993. MHC haplotype influences primary Giardia muris infections in H-2 congenic strains of mice. Int J Parasitol 23(5):661-4. [PubMed: 8225770] [MGI Ref ID J:21687]
Wang L; Han R; Lee I; Hancock AS; Xiong G; Gunn MD; Hancock WW. 2005. Permanent survival of fully MHC-mismatched islet allografts by targeting a single chemokine receptor pathway. J Immunol 175(10):6311-8. [PubMed: 16272282] [MGI Ref ID J:119345]
Zhang ZX; Yang L; Young KJ; DuTemple B; Zhang L. 2000. Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression. Nat Med 6(7):782-9. [PubMed: 10888927] [MGI Ref ID J:118729]
Zhou P; Szot GL; Guo Z; Kim O; He G; Wang J; Grusby MJ; Newell KA; Thistlethwaite JR; Bluestone JA; Alegre ML. 2000. Role of STAT4 and STAT6 signaling in allograft rejection and CTLA4-Ig-mediated tolerance. J Immunol 165(10):5580-7. [PubMed: 11067913] [MGI Ref ID J:119580]
Zosky GR; Larcombe AN; White OJ; Burchell JT; von Garnier C; Holt PG; Turner DJ; Wikstrom ME; Sly PD; Stumbles PA. 2009. Airway hyperresponsiveness is associated with activated CD4+ T cells in the airways. Am J Physiol Lung Cell Mol Physiol 297(2):L373-9. [PubMed: 19482896] [MGI Ref ID J:151339]
Apostolou I; Hao Z; Rajewsky K; von Boehmer H. 2003. Effective destruction of Fas-deficient insulin-producing beta cells in type 1 diabetes. J Exp Med 198(7):1103-6. [PubMed: 14530378] [MGI Ref ID J:85985]
Bercovici N; Heurtier A; Vizler C; Pardigon N; Cambouris C; Desreumaux P; Liblau R. 2000. Systemic administration of agonist peptide blocks the progression of spontaneous CD8-mediated autoimmune diabetes in transgenic mice without bystander damage. J Immunol 165(1):202-10. [PubMed: 10861053] [MGI Ref ID J:62874]
Guo Z; Dose M; Kovalovsky D; Chang R; O'Neil J; Look AT; von Boehmer H; Khazaie K; Gounari F. 2007. Beta-catenin stabilization stalls the transition from double-positive to single-positive stage and predisposes thymocytes to malignant transformation. Blood 109(12):5463-72. [PubMed: 17317856] [MGI Ref ID J:145430]
Hernandez J; Aung S; Redmond WL; Sherman LA. 2001. Phenotypic and functional analysis of CD8(+) T cells undergoing peripheral deletion in response to cross-presentation of self-antigen. J Exp Med 194(6):707-17. [PubMed: 11560988] [MGI Ref ID J:100011]
Kreuwel HT; Biggs JA; Pilip IM; Pamer EG; Lo D; Sherman LA. 2001. Defective CD8+ T cell peripheral tolerance in nonobese diabetic mice. J Immunol 167(2):1112-7. [PubMed: 11441123] [MGI Ref ID J:107321]
Kreuwel HT; Morgan DJ; Krahl T; Ko A; Sarvetnick N; Sherman LA. 1999. Comparing the relative role of perforin/granzyme versus Fas/Fas ligand cytotoxic pathways in CD8+ T cell-mediated insulin-dependent diabetes mellitus. J Immunol 163(8):4335-41. [PubMed: 10510373] [MGI Ref ID J:100013]
Lyman MA; Aung S; Biggs JA; Sherman LA. 2004. A spontaneously arising pancreatic tumor does not promote the differentiation of naive CD8+ T lymphocytes into effector CTL. J Immunol 172(11):6558-67. [PubMed: 15153470] [MGI Ref ID J:90532]
Lyman MA; Nugent CT; Marquardt KL; Biggs JA; Pamer EG; Sherman LA. 2005. The fate of low affinity tumor-specific CD8+ T cells in tumor-bearing mice. J Immunol 174(5):2563-72. [PubMed: 15728462] [MGI Ref ID J:97745]
Martinez X; Kreuwel HT; Redmond WL; Trenney R; Hunter K; Rosen H; Sarvetnick N; Wicker LS; Sherman LA. 2005. CD8+ T Cell Tolerance in Nonobese Diabetic Mice Is Restored by Insulin-Dependent Diabetes Resistance Alleles. J Immunol 175(3):1677-85. [PubMed: 16034108] [MGI Ref ID J:100008]
Morgan DJ; Kreuwel HT; Fleck S; Levitsky HI; Pardoll DM; Sherman LA. 1998. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J Immunol 160(2):643-51. [PubMed: 9551898] [MGI Ref ID J:45169]
Morgan DJ; Kurts C; Kreuwel HT; Holst KL; Heath WR; Sherman LA. 1999. Ontogeny of T cell tolerance to peripherally expressed antigens. Proc Natl Acad Sci U S A 96(7):3854-8. [PubMed: 10097127] [MGI Ref ID J:109899]
Morgan DJ; Liblau R; Scott B; Fleck S; McDevitt HO; Sarvetnick N; Lo D; Sherman LA. 1996. CD8(+) T cell-mediated spontaneous diabetes in neonatal mice. J Immunol 157(3):978-83. [PubMed: 8757600] [MGI Ref ID J:99756]
Morgan DJ; Nugent CT; Raveney BJ; Sherman LA. 2004. In a transgenic model of spontaneous autoimmune diabetes, expression of a protective class II MHC molecule results in thymic deletion of diabetogenic CD8+ T cells. J Immunol 172(2):1000-8. [PubMed: 14707073] [MGI Ref ID J:100010]
Pauza ME; Nguyen A; Wolfe T; Ho IC; Glimcher LH; von Herrath M; Lo D. 2001. Variable effects of transgenic c-Maf on autoimmune diabetes. Diabetes 50(1):39-46. [PubMed: 11147792] [MGI Ref ID J:133138]
Redmond WL; Marincek BC; Sherman LA. 2005. Distinct requirements for deletion versus anergy during CD8 T cell peripheral tolerance in vivo. J Immunol 174(4):2046-53. [PubMed: 15699134] [MGI Ref ID J:100009]
Redmond WL; Wei CH; Kreuwel HT; Sherman LA. 2008. The apoptotic pathway contributing to the deletion of naive CD8 T cells during the induction of peripheral tolerance to a cross-presented self-antigen. J Immunol 180(8):5275-82. [PubMed: 18390708] [MGI Ref ID J:134242]
Shanker A; Brooks AD; Jacobsen KM; Wine JW; Wiltrout RH; Yagita H; Sayers TJ. 2009. Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity. Cancer Res 69(16):6615-23. [PubMed: 19654302] [MGI Ref ID J:151764]
Smith SS; Patterson T; Pauza ME. 2005. Transgenic Ly-49A inhibits antigen-driven T cell activation and delays diabetes. J Immunol 174(7):3897-905. [PubMed: 15778344] [MGI Ref ID J:97982]
VanOosten RL; Griffith TS. 2007. Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy. Cancer Res 67(24):11980-90. [PubMed: 18089829] [MGI Ref ID J:129272]
Health & husbandry
Health & Colony Maintenance Information
Currently there no information available for this strain. This may be due to the supply level of this strain.
Purchasing information
Pricing, Supply Level & Notes, Controls, General Terms & Conditions
Pricing
| Pricing for USA, Canada and Mexico shipping destinations |
|
Animals Provided
Price (US dollars $) Cryorecovery Fee $1900.00 Cryopreserved Embryos $1600.00 At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.
Additional Supply Details
| Pricing for International shipping destinations |
|
Animals Provided
Price (US dollars $) Cryorecovery Fee $2470.00 Cryopreserved Embryos $2080.00 At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.
Additional Supply Details
|
|
|
Supply Details
| Standard Supply | Cryopreserved. Ready for recovery. Please refer to pricing and supply notes for further information. |
|---|---|
| Supply Notes |
|
Control Information
| Control | ||
|---|---|---|
| 000463 B10.D2-Hc1 H2d H2-T18c/nSnJ | (approximate) | |
| Stock number 000463 - B10.D2-Hc1 H2d H2-T18c/nSnJ serves as an approximate control. | ||
| Considerations for Choosing Controls | ||
| USA, Canada and Mexico - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
| International - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
Payment Terms and Conditions
Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.
See Terms of Use tab for General Terms and Conditions
The Jackson Laboratory's Genotype Promise
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.Ordering and Purchasing Information
Purchasing Information
JAX® Mice Orders
Surgical Services
Contact Information
Orders & Technical Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form
Terms of Use
Terms of Use
General Terms and Conditions
For Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.
Contact information
General inquiries
Contracts Administration
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
JAX® Mice, Products & Services Conditions of Use
"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.No Warranty
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.
No Liability
In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. In purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.
MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.
Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.